Type:10 Tablets
Generic Name:Methylphenidate Hydrochloride
Manufacturer:General Pharmaceuticals Ltd.
Price:৳170.00
Narcolepsy, Attention Deficit Hyperactivity Disorder
Should be taken on an empty stomach. Take 30-45 min before meals.
Oral Narcolepsy Adult: 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate Attention Deficit Hyperactivity Disorder 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate
Oral Narcolepsy Child >6 years: 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID Narcolepsy 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day <6 years: Safety and efficacy not established
Marked anxiety, tension, agitation; glaucoma; Tourette's syndrome or tics. Known severe structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac disorders that could increase the risk of sudden death. Extended-release form: Severe hypertension, heart failure, arrhythmia, hyperthyroidism, recent MI or angina.
Methylphenidate is a central stimulant and indirect-acting sympathomimetic.
Pregnancy and lactation. History of alcohol or drug abuse. Hypertension and other CV disorders that might be exacerbated by increases in BP or heart rate. Pre-existing psychosis or bipolar disorder; monitor for symptoms of aggression or hostility. History of seizure disorder. Children <6 yr (growth suppression); monitor growth during therapy. May impair ability to drive or operate machinery. Transdermal: Avoid exposure of application site to any direct external heat source. Lactation: Unknown; avoid during breastfeeding; use caution
Angina, arrhythmia, cerebral arteritis, cerebral occlusion, changes in BP, MI, necrotising vasculitis, palpitation, pulse changes, tachycardia; depression, dizziness, drowsiness, fever, headache, insomnia, nervousness, neuroleptic malignant syndrome (NMS), Tourette's syndrome, toxic psychosis; erythema multiforme, exfoliative dermatitis, hair loss, rash, urticaria; growth retardation; abdominal pain, anorexia, diarrhoea, nausea, vomiting, weight loss; anaemia, leukopenia, thrombocytopenic purpura, thrombocytopenia; abnormal LFTs, hepatic coma, increased transaminases; arthralgia, dyskinesia; blurred vision, visual accommodation disturbance; cough, pharyngitis, sinusitis, upper respiratory tract infection; accidental injury, hypersensitivity. Transdermal: Insomnia, decreased appetite; nausea; tic, emotional instability; vomiting, anorexia; nasal congestion, nasopharyngitis; weight loss.
May reduce effects of antihypertensive agents. Reduced serum level with carbamazepine. Increased serum levels or effects with CYP2D6 inhibitors e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, ropinirole. May increase serum levels of phenytoin, TCAs. Possible severe hypertension and tachycardia with sibutramine. CNS depression with alcohol. Potentially Fatal: Severe toxic reactions with clonidine. Increased risk of hypertensive crisis with MAOIs.